N
early all humans worldwide harbor persistent Epstein-Barr virus (EBV) infection by adulthood (1, 2) . This lifelong viral infection is asymptomatic in the vast majority of humans due to control of persistent EBV infection by viral immunity. However, persistent EBV infection is associated with the development of cancers such as Burkitt and Hodgkin lymphomas and nasopharyngeal and gastric carcinomas, which typically arise decades after initial EBV infection (3) .
T cell-mediated responses are known to be important for controlling persistent EBV infection since immunosuppression can result in EBV-induced lymphomas in AIDS and transplant patients (4) . Furthermore, adoptive transfer of EBV-specific T cells can be preventive or therapeutic against EBV-induced lymphomas in transplant patients (5, 6) . Thus, vaccination strategies that enhance EBV immunity may lead to an effective EBV cancer vaccine by reducing the number of virus-infected cells or attacking EBV-positive tumor cells.
EBNA-1 is an EBV nuclear protein expressed in both lytic (7) and latent phases of EBV infection, and it is consistently expressed in all EBV-associated cancers (8) (9) (10) (11) . The presence of purine-enriched Gly-Ala repeats in the EBV EBNA-1 sequence inhibits RNA translation (12) (13) (14) and restricts antigen presentation for CD8 ϩ T cells in vitro (15, 16) . Nevertheless, studies have shown that EBNA-1-specific CD4 ϩ and CD8 ϩ T cells are frequently detected in EBV-infected hosts (17) (18) (19) , and both T cell subsets can be effective in controlling growth of EBV-immortalized B cells in vitro (20, 21) .
Rhesus macaques provide the most accurate animal model for EBV infection, because both the human and nonhuman hosts and pathogens share a high degree of genetic and biologic similarities (22) (23) (24) (25) . They are naturally infected with an EBV-related gamma-1-herpesvirus or lymphocryptovirus (LCV) that shares an identical repertoire of viral genes with EBV (25) . The rhesus LCV EBNA-1 homologue (rhEBNA-1) shares approximately 50% amino acid similarity with EBV EBNA-1 (25) , has identical molecular functions (26) , and, although not a dominant antigen (2) , is frequently targeted by both CD4 ϩ and CD8 ϩ T cells in LCVinfected macaques (27, 28) . Since only 2 peptides containing rhEBNA-1-specific T cell epitopes have been described in this animal model (27) , the goal of our study was to investigate whether the rhEBNA-1-specific T cell response could be expanded in vivo by EBNA-1 vaccination with a specific focus on defining the EBNA-1 T cell epitopes recognized before and after vaccination.
Forty adult rhesus macaques were randomly screened for rhLCV-specific humoral and rhEBNA-1-specific cellular responses, and 15 animals were chosen based on positive rhLCV serology and low positive rhEBNA-1-specific cellular responses (28) . The animals were cared for in conformance to the Committee on the Care and Use of Laboratory Animals guidelines (29) . All experimental protocols and procedures were approved by the Emory Institutional Animal Care and Use Committee. Assigned animals were divided into 3 groups and immunized twice via the intramuscular route with replication-defective chimpanzee-derived adenovirus vectors (AdC) containing different constructs. Serotype AdC68 was used for priming and AdC6 for boosting immunization. AdC vectors have been shown to stimulate robust transgene product-specific T cell responses in nonhuman primates (30, 31) and do not cross-react with human or rhesus macaque adenovirus serotypes (32) , avoiding preexisting immunity against the vaccine constructs. The constructs encoded a herpes simplex virus 1 glycoprotein D (SgD) domain fused with an irrelevant antigen (influenza virus nucleoprotein [NP]) or rhEBNA-1 deleted for the Gly-Ala repeats. The rationale for using the SgD domain in the rhEBNA-1 vaccine constructs is related to its enhanced binding to the herpesvirus entry mediator (HVEM) compared to that of gD (33) , blocking the protein interaction between HVEM and the B and T lymphocyte activator (BTLA) and consequently inhibiting the negative regulatory pathways of T cell activation (34) . Also, antigens fused to gD have shown enhanced immune responses to antigens (35) . An illustration representing the different constructs used in this study can be seen in Fig. 1A . A detailed description of these chimpanzeederived recombinant adenovirus constructs are provided by R. M. Leskowitz, M. H. Fogg, X. Zhou, A. Kaur, E. L. V. Silveira, F. Villinger, P. M. Lieberman, F. Wang, and H. C. Ertl (submitted for publication). Group I animals were vaccinated with the AdCSgD-NP construct (36) , group II animals were vaccinated with the AdCSgD-rhEBNA-1 construct, and group III animals were vaccinated with a construct containing an identical rhEBNA-1 but fused to a mutated SgD version incapable of blocking the BTLA-HVEM interaction (AdCNBEFSgDrhEBNA-1) (35) ( RhEBNA-1-specific T cell epitopes were identified from peripheral blood mononuclear cells (PBMCs) collected pre-and postimmunization by first pulsing cells with a peptide library spanning rhEBNA-1 (GeneMed Synthesis; 15-mer peptides overlapping by 5 amino acids). Excess peptide was removed by washing, and then cells were cultured with rhesus interleukin 7 (rhIL-7) (25 ng/ml; Resource for Nonhuman Primate Immune Reagents, Emory University) and human interleukin 2 (hIL-2) (50 IU/ml; Roche). After 12 to 16 days, cultured cells were restimulated with pools, subpools, or single peptides on gamma interferon (IFN-␥) enzyme-linked immunosorbent spot (ELISPOT) assay to identify reactivity to specific peptides (17, 27, 37) .
A representative epitope-mapping experiment is shown for Rm2-4 (Fig. 2) . Initially, T cell responses recognized 1 of 3 peptide pools (pool B) containing 17 overlapping peptides, 1 of 3 peptide subpools (subpool B3) containing 5 of the original 17 peptides ( Fig. 2A) , and finally peptide 34 (Fig. 2B) . CD8 ϩ T cells were responding to peptide 34 based on CD4 ϩ or CD8 ϩ cell depletions performed with specific Dynabeads (Dynal), followed by IFN-␥ ELISPOT assay (Fig. 2C) . Testing of multiple 9-mer derivatives of peptide 34 showed an optimal response to peptide 34-3 (RGFKK FENM), which had increased responses compared to those of the original 15-mer peptide 34 (Fig. 2D) . Other peptide 34-derived sequences induced lower responses. Of note, peptide 34 is identical to one reported previously as able to stimulate CD8 ϩ T cell cytotoxicity (27) .
Using an in silica algorithm (38, 39) , the optimal CD8 ϩ T cell epitope (peptide 34-3) for Rm2-4 was predicted as a strong binder to Mamu-B*029 ( Fig. 2E; A ϩ APCs (Fig. 2F) . These data were confirmed independently using CD4 ϩ cell-depleted PBMCs from 3 Mamu-B*029 ϩ animals from another cohort (data not shown). Although both alleles are part of the same inherited haplotype (40), they have different peptide-binding motifs, and only Mamu-B*029 presented the identified epitope.
Using this approach, a total of 10 rhEBNA-1 peptide responses were identified among 8 of the 15 animals ( Table 1) . Five of the rhEBNA-1-specific responses were from CD8 ϩ T cells, 2 were from CD4 ϩ T cells, 1 was equivocal after cell depletion studies, and 2 were not tested. Eight of the epitopes were mapped to individual peptides, and 2 were mapped to the level of peptide pools. All of the rhEBNA-1 peptides recognized are located in the carboxy terminus of rhEBNA-1, similar to EBV EBNA-1 in humans 
(2). Three additional CD8
ϩ epitopes plus one CD4 ϩ epitope have also been mapped to 15-mer peptides (Table 1) . Finally, we defined the exact sequences of rhEBNA-1 CD8 ϩ (RGFKKFENM) and CD4 ϩ (RLTPLGRLPFGYAP) T cell epitopes in distinct animals (data not shown).
The rhEBNA-1 therapeutic immunizations either markedly expanded existing responses or appeared to elicit novel ones when comparing preimmunization and post-boost immunization time points in responder animals ( Table 1) . rhEBNA-1-specific responses were not enhanced after AdCSgD-NP vaccinations in the control group 1 animals. But in group 2 and 3 animals, rhEBNA-1 peptide-specific responses were detected in 4/12 animals before immunization and in 8/12 animals after rhEBNA-1 vaccination. In the 4 animals for which rhEBNA-1-specific responses were detected before immunization, the preexisting responses were augmented in a range of 4.5-to 28.8-fold after boost immunization (Table 1) . In 5 animals, 6 rhEBNA-1 epitopes were detected only after boost vaccination. There was no convincing evidence that an HVEM-binding SgD domain enhanced the response among the small numbers of animals in group 2 versus group 3. However, the combined results of animals in groups 2 and 3 suggest that rhEBNA-1-specific responses were enhanced by rhEBNA-1 vaccination.
To confirm these findings, a Mamu-B*029-RGFKKFENM tetramer was synthesized (NIH Tetramer Core Facility) and tested for staining of rhEBNA-1-specific CD8 ϩ T cells in expanded cells from Rm2-4 (Mamu-B*029 ϩ ) collected preimmunization and post-boost immunizations. The gating strategy for the quantification of the tetramer-positive cells is described for Fig. 3A . While Mamu-B*029 Ϫ cells collected 2 weeks after boost immunization and Mamu-B*029 ϩ collected before immunization stained negative, cells from the same Mamu-B*029 ϩ animal collected 2 weeks after the primary but mainly after the boost immunization showed clear staining with the tetramer (Fig. 3B) . Cultured cells from another Mamu-B*029 ϩ animal (Rm2-5) failed to identify peptide 34-3 by IFN-␥ ELISPOT assay, but a small population reacted with the tetramer after the boost immunization ( Fig. 3B  and C) .
A concern for the development of vaccine/immunotherapy against EBV is the potential to elicit autoimmune responses (41) (42) (43) (44) . All animal plasma samples collected post-booster immunization were, however, negative for autoantibodies to Sm, ribonucleoprotein, Scl-70, SSA/Ro, SSB/La, histidil tRNAsynthetase, and CENP-B (data not shown), suggesting our approach to be safe.
Enhancing immune responses to subdominant antigens can confer some degree of protection against several infections (45) (46) (47) (48) (49) . Pathogens like EBV restrict host T cell responses during infection, facilitating pathogen replication and/or persistence by avoiding broader immune responses. Recent studies also showed that EBNA-1-specific responses are reduced in nasopharyngeal carcinoma patients compared to those in healthy EBV ϩ donors (17). Therefore, our results suggest that the mapping of new rhEBNA-1 epitopes provides important tools for studying vaccination strategies in the rhesus macaque animal model, and EBNA-1 responses can be increased by vaccination in persistently infected hosts.
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